News Update: Inspire Pharma Shares Down 6.5% After Eye Drug Didn't Achieve Significant Results

Inspire Pharmaceuticals (NASDAQ:ISPH) shares dropped 6.5% to $6.60 after the company said that its eye drug Azasite didn't achieve significant results during a trial as treatment of blepharitis. Blepharitis is a condition where the margins of the eyelids become irritated. The company said that the drug was not more effective than InSite Vision's drug DuraSite. The drug is already approved as a treatment for conjunctivitis.